$BNGO

Bionano Genomics (Nasdaq: BNGO) said 13 studies published in 2026 covering 730 samples across multiple countries evaluated optical genome mapping (OGM) for structural-variant detection in reproductive health and prenatal genetic disorders. The company cited results including 1-in-4 diagnoses in unexplained infertility (220 subjects) and up to 99.03% prenatal concordance (217 samples).

Bionano Genomics director Kristiina Vuori, MD, was granted 9,149 stock options at an exercise price of $1.19 per share. These options, part of her compensation, will vest in equal monthly installments over 12 months or fully upon a Change of Control, and expire on May 13, 2036. This transaction is considered a neutral event in terms of filing impact and sentiment, as it represents equity compensation rather than an open-market purchase.

Bionano Genomics, Inc. (BNGO) reported a Q1 loss of $0.76 per share, outperforming the Zacks Consensus Estimate of a $0.81 loss and surpassing year-ago revenues. The company posted revenues of $6.69 million for the quarter ended March 2026, beating estimates by 2.88%. Despite an underperforming stock year-to-date, its earnings outlook is favorable, earning it a Zacks Rank #2 (Buy).

Bionano Genomics, Inc. (Nasdaq: BNGO) announced it will report its first quarter 2026 financial results and discuss recent corporate progress during a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time. Interested parties can register for the event and a replay will be available on the company's investor relations website for at least 30 days.

H.C. Wainwright has lowered its price target for Bionano Genomics (NASDAQ:BNGO) to $6 from $7, while maintaining a Buy rating. This adjustment is primarily due to an increased share count, despite the stock trading near its 52-week low and an InvestingPro analysis suggesting it may be undervalued. Bionano Genomics reported a revenue decline for Q4 2025 and the full year 2025, but management provided 2026 revenue guidance indicating potential topline growth of up to 16%.

Bionano Genomics reported preliminary unaudited financial results for Q4 and full-year 2025, highlighting a pivotal year of business model transformation, improved financial profile, and expanded adoption of optical genome mapping (OGM) solutions. The company anticipates full-year 2025 revenue between $28.4 million and $28.6 million, with 32 new OGM systems installed, bringing the total installed base to 387. Bionano also noted significant reimbursement progress and growth in published clinical research supporting OGM.

Image source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...

SAN DIEGO, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Bionano Genomics, Inc. ( NASDAQ:BNGO ) today announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showing how optical genome mapping ( OGM ) can address key limitations of targeted RNA-sequencing ( ...

SAN DIEGO, Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- Bionano Genomics, Inc. ( NASDAQ: BNGO ) ( "Bionano" or the "Company" ) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company's common stock ( or common stock equivalents in lieu ...

SAN DIEGO, Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- Bionano Genomics, Inc.